Suresh Vazirani

“Calbiotech Inc. and Dr Noori Barka have developed an excellent range of immunoassay products that will complement our growing range of diagnostic products. Globally, the immunology segment of the IVD Industry is valued at around USD 15 billion. Calbiotech’s expertise in immunoassay will allow us to strengthen our position in this high-growth market and integrate their strong R&D program to further enhance the product development strategy of the Transasia-Erba Group.”

Suresh Vazirani,
Chairman & Managing Director,
Transasia-Erba Group

Transasia Bio-Medicals Ltd. has acquired Calbiotech Group of Companies, USA, through its German subsidiary Erba Mannheim. This is the 14th overseas IVD acquisition by Transasia in the last 8 years. Calbiotech based in Spring Valley, California, is the first company to introduce immunoassay kits in the United States to detect antibodies against Zika virus in human blood. It is also known to develop innovative products for the emerging markets. It has more than 200 products, distributed to more than 60 countries.

With this acquisition, Transasia is all set to strengthen its foray into ELISA and CLIA assays for human and animal research, including specific assays for autoimmune disorders, cancer, and infectious diseases. Over the years, Transasia has been meeting the needs of the emerging markets through innovative and cutting-edge technologies designed and developed at its global, state-of-the-art facilities.


Digital version